Gu Joyce Hanyue, Samarneh Mark
Lake Erie College of Osteopathic Medicine, Medical School, Seton Hill, PA USA.
St. John's Riverside Hospital, Yonkers, NY USA.
J Diabetes Metab Disord. 2025 Jan 2;24(1):33. doi: 10.1007/s40200-024-01552-x. eCollection 2025 Jun.
Glucagon-like peptide 1 (GLP-1) receptor agonists have recently proven to be an effective treatment for type 2 diabetes mellitus (T2DM). However, these drugs are also known to carry a significant risk of drug-induced pancreatitis. The purpose of this study is to determine whether or not GLP-1-associated pancreatitis risk is dose-dependent. That is, we aim to determine whether the risk of developing pancreatitis increases with the administered dose of GLP-1 agonist or not.
We conduct a retrospective case control study using data taken from the U.S. Food and Drug Administration Adverse Events Reporting System (FAERS) database. Participants are included if they reported an adverse effect of GLP-1 agonist and reported the cumulative dose of drug administered. We measure the odds ratio of developing pancreatitis between patients who have taken a large cumulative dose of GLP-1 agonist and those with a low cumulative dose of GLP-1 agonist. The odds ratio of different GLP-1 agonists are combined via a random effects model.
Patients with a high cumulative dose of GLP-1 agonist are associated with a higher risk of developing drug-induced pancreatitis associated with GLP-1 agonists, indicated by a statistically significant odds ratio. Furthermore, the odds ratio increases as the cumulative dose increases.
GLP-1 agonists are associated with significant pancreatitis risk which increases with larger cumulative doses.
胰高血糖素样肽1（GLP-1）受体激动剂最近已被证明是治疗2型糖尿病（T2DM）的有效药物。然而，这些药物也已知会带来药物性胰腺炎的重大风险。本研究的目的是确定GLP-1相关的胰腺炎风险是否呈剂量依赖性。也就是说，我们旨在确定胰腺炎的发生风险是否会随着GLP-1激动剂给药剂量的增加而增加。
我们使用从美国食品药品监督管理局不良事件报告系统（FAERS）数据库获取的数据进行了一项回顾性病例对照研究。如果参与者报告了GLP-1激动剂的不良反应并报告了给药的累积剂量，则将其纳入研究。我们测量服用高累积剂量GLP-1激动剂的患者与服用低累积剂量GLP-1激动剂的患者之间发生胰腺炎的比值比。通过随机效应模型合并不同GLP-1激动剂的比值比。
GLP-1激动剂累积剂量高的患者发生与GLP-1激动剂相关的药物性胰腺炎的风险更高，比值比具有统计学意义。此外，比值比随着累积剂量的增加而增加。
GLP-1激动剂与显著的胰腺炎风险相关，且随着累积剂量的增加而增加。
